Flivas


Indications and Reactions:

Role Indications Reactions
Secondary
Benign Prostatic Hyperplasia 16.5%
Hypertension 12.9%
Type 2 Diabetes Mellitus 10.6%
Hypertonic Bladder 9.4%
Constipation 7.6%
Diabetes Mellitus 5.9%
Dysuria 5.9%
Herpes Zoster 4.7%
Drug Use For Unknown Indication 4.1%
Product Used For Unknown Indication 4.1%
Delirium 2.4%
Pollakiuria 2.4%
Post Herpetic Neuralgia 2.4%
Angina Pectoris 1.8%
Chronic Hepatitis C 1.8%
Dementia 1.8%
Dementia With Lewy Bodies 1.8%
Prostate Cancer 1.8%
Atrial Fibrillation 1.2%
Cerebral Infarction 1.2%
Hepatic Function Abnormal 23.7%
Parkinsonism 10.5%
Prostate Cancer 10.5%
Atrioventricular Block Complete 5.3%
Prothrombin Time Prolonged 5.3%
Urinary Retention 5.3%
Urticaria 5.3%
Alanine Aminotransferase Increased 2.6%
Aspermia 2.6%
Cataract 2.6%
Dermatitis Exfoliative 2.6%
Dyspnoea Exertional 2.6%
Dysuria 2.6%
Ecg Signs Of Myocardial Ischaemia 2.6%
Hypoaesthesia 2.6%
Loss Of Consciousness 2.6%
Malaise 2.6%
Pneumonia Primary Atypical 2.6%
Rash 2.6%
Red Blood Cell Count Decreased 2.6%
Concomitant
Benign Prostatic Hyperplasia 18.4%
Product Used For Unknown Indication 14.3%
Hypertension 10.9%
Prophylaxis 8.6%
Rheumatoid Arthritis 4.6%
Prostate Cancer Stage Iv 4.5%
Metastatic Renal Cell Carcinoma 4.2%
Prostate Cancer 3.9%
Constipation 3.7%
Insomnia 3.5%
Gastritis 3.5%
Cardiac Failure Chronic 2.7%
Dysuria 2.6%
Renal Cell Carcinoma 2.3%
Drug Use For Unknown Indication 2.2%
Diabetes Mellitus 2.1%
Depression 2.0%
Hypertonic Bladder 2.0%
Gastric Ulcer 1.9%
Colorectal Cancer 1.9%
Prostate Cancer 8.1%
Interstitial Lung Disease 7.2%
Pyrexia 7.2%
Rhabdomyolysis 7.2%
Vomiting 7.2%
Stomatitis 6.8%
Urinary Retention 6.3%
White Blood Cell Count Decreased 5.4%
Renal Impairment 5.0%
Cerebral Infarction 4.5%
Palmar-plantar Erythrodysaesthesia Syndrome 4.5%
Pneumonia 4.5%
White Blood Cell Count Increased 4.5%
Hepatic Function Abnormal 3.6%
Myocardial Infarction 3.2%
Pancreatitis 3.2%
Sepsis 3.2%
Death 2.7%
Renal Failure Acute 2.7%
Somnolence 2.7%

Drug Data